# A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

> **NCT05924438** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Professor Francois Venter** · enrollment: 600 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Delstrigo
- **DRUG:** KOCITAF

## Key facts

- **NCT ID:** NCT05924438
- **Lead sponsor:** Professor Francois Venter
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-08
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05924438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05924438, "A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05924438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*